PMID- 36913708
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230529
IS  - 1349-9157 (Electronic)
IS  - 0449-3060 (Print)
IS  - 0449-3060 (Linking)
VI  - 64
IP  - 3
DP  - 2023 May 25
TI  - Effectiveness of proton beam therapy for liver oligometastatic recurrence in 
      patients with postoperative esophagus cancer.
PG  - 582-589
LID - 10.1093/jrr/rrad009 [doi]
AB  - There are several reports of hepatic resection for postoperative hepatic 
      metastatic recurrence of esophageal cancer. However, it is unclear whether 
      surgery is the best local treatment for liver metastases. Thus, this study aimed 
      to retrospectively analyze proton beam therapy (PBT) for postoperative liver 
      metastatic recurrence of esophageal cancer without extrahepatic lesions and 
      examine outcomes and adverse events. This single-center historical cohort study 
      selected patients who underwent PBT at our proton therapy center between 2012 and 
      2018. The patients were selected based on the following criteria: primary 
      esophagus carcinoma was resection and metachronous liver oligometastasis 
      recurrence without extrahepatic tumors and no more than three liver metastases. 
      This study included seven males with a median age of 66 (range, 58-78) years, and 
      15 lesions were included in the study. The median tumor size was 22.6 (7-55.3) 
      mm. The most frequent dose was 72.6 Gy relative biological effect (RBE)/22 
      fractions (fr) for four lesions and 64 Gy (RBE)/8 fr for four lesions. The median 
      survival time was 35.5 (13.2-119.4) months. The 1-, 2- and 3-year overall 
      survival (OS) rates were 100%, 57.1% and 42.9%, respectively. The median 
      progression-free survival (PFS) time was 8.7 (1.2-44.1) months. The 1-, 2- and 
      3-year PFS rates were 28.6%. The 1-, 2- and 3-year local control (LC) rates were 
      100%. No grade >/=4 radiation-induced adverse events (AEs) were observed. We 
      conclude that PBT can be considered an alternative to hepatic resection for 
      recurrent liver metastases postoperative esophageal cancer.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of The 
      Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
FAU - Yamaguchi, Hisashi
AU  - Yamaguchi H
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima City, Fukushima 960-1295, Japan.
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Kato, Takahiro
AU  - Kato T
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Honda, Michitaka
AU  - Honda M
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima City, Fukushima 960-1295, Japan.
AD  - Department of Surgery, Southern Tohoku General Hospital, Koriyama City, Fukushima 
      963-8563, Japan.
FAU - Hamada, Koichi
AU  - Hamada K
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima City, Fukushima 960-1295, Japan.
AD  - Department of Gastroenterology, Southern Tohoku General Hospital, Koriyama City, 
      Fukushima 963-8563, Japan.
FAU - Seto, Ichiro
AU  - Seto I
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Tominaga, Takuya
AU  - Tominaga T
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Takagawa, Yoshiaki
AU  - Takagawa Y
AD  - Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical 
      University, Fukushima City, Fukushima 960-1295, Japan.
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Takayama, Kanako
AU  - Takayama K
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Suzuki, Motohisa
AU  - Suzuki M
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Kikuchi, Yasuhiro
AU  - Kikuchi Y
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
FAU - Teranishi, Yasushi
AU  - Teranishi Y
AD  - Department of Surgery, Southern Tohoku General Hospital, Koriyama City, Fukushima 
      963-8563, Japan.
FAU - Murakami, Masao
AU  - Murakami M
AD  - Department of Radiology, Southern Tohoku Proton Therapy Center, Koriyama City, 
      Fukushima 963-8052, Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Radiat Res
JT  - Journal of radiation research
JID - 0376611
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - *Proton Therapy/adverse effects
MH  - Cohort Studies
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/radiotherapy
MH  - *Esophageal Neoplasms/radiotherapy
MH  - *Liver Neoplasms/radiotherapy/surgery
PMC - PMC10214986
OTO - NOTNLM
OT  - esophagus cancer
OT  - liver metastatic
OT  - proton therapy
COIS- The authors declare they have no conflicts of interest to report.
EDAT- 2023/03/14 06:00
MHDA- 2023/05/29 06:41
PMCR- 2023/03/13
CRDT- 2023/03/13 17:32
PHST- 2022/09/21 00:00 [received]
PHST- 2022/11/07 00:00 [revised]
PHST- 2023/05/29 06:41 [medline]
PHST- 2023/03/14 06:00 [pubmed]
PHST- 2023/03/13 17:32 [entrez]
PHST- 2023/03/13 00:00 [pmc-release]
AID - 7076640 [pii]
AID - rrad009 [pii]
AID - 10.1093/jrr/rrad009 [doi]
PST - ppublish
SO  - J Radiat Res. 2023 May 25;64(3):582-589. doi: 10.1093/jrr/rrad009.